In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:

• Navigate from VCF to final report with speed, precision, and confidence;
• Easily issue report addendums without the need for re-running a VCF;
• Streamline structural variant filtering based on user-set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;
• Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one click.

As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insights (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time.

In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:

• Navigate from VCF to final report with speed, precision, and confidence;
• Easily issue report addendums without the need for re-running a VCF;
• Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;
• Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click.

In its latest release, QCI Interpret advances market-leading NGS interpretation software with artificial intelligence-driven insights to enable clinical exome completeness.

We are pleased to announce that the 2023 Release of QCI Interpret, QIAGEN’s decision support software platform for the annotation, classification, and reporting of somatic and germline variants, is now available.

Expanding on the software’s current capabilities, the QCI Interpret 2023 Release extends its market-leading, unrivalled content with further advancements in Artificial Intelligence (AI) to enable clinical exome completeness, enhanced phenotype driven ranking, and improved literature searches.

READ PRESS RELEASE

QCI Interpret 2023 Release highlights for hereditary and oncology applications

• QCI Interpret leverages artificial intelligence (AI) to expand the bibliography: To provide broader coverage of the clinical exome, AI-derived literature references have been integrated into the Bibliography section. The new Source icons, “Context” disease details, and “Show Phenotype-Related References Only” filter provide full control over the use of these automatically extracted references.    

• Enhanced, AI-trained phenotype-driven ranking: Variant-specific qualities are now taken into account beyond the similarity of the gene–disease phenotypic spectrum to patient symptoms by providing an improved PDR score ranking of candidate variants for rapid clinical exome review. 

• Improved ACMG PVS1 criteria with the modified strength workflow and informative notices: ClinGen's PVS1-modified strength recommendations are now applied to improve the ACMG classification of loss of function variants. PVS1 notices indicate the specific decision tree branch applied. 

• Gene transcripts with MANE select status are now the default: QCII embraces this community effort to standardize clinical transcripts for reporting. “MANE Select” and “MANE Plus Clinical” labels appear in the variant viewer dropdown, in the "Effect on Protein" section of the Variant Details page.   

• More precise structural variant filtering: The Confidence filter now supports thresholds for copy number gains, losses, fusions, and rearrangements. A “gene-associated structural variants” filter enables retention of structural variants that are partly in non-coding gene regions.    

• Enhanced accuracy of the Somatic reporting policy: The 1-year expiration was removed for user set assessments in Somatic reporting policies v1 and v2. User assessments are now automatically re-reported indefinitely in new cases for all reportability types, including artifacts. 

• New workflows for streamlined report revisioning and labeling: A new Label Report button on the Review and Report page enables the addition (or removal) of a report label including Addendum, Amendment, Correction, or custom text. The new Addend Report button on signed out tests creates a copy, that is labeled with Addendum, to facilitate issuing an updated report. API enhancements enable a new report to replace an existing one (correction) or creation of an amended/addended report copied from an existing report with updated information (such as patient or physician information) provided via the API. The report label can be displayed on customized reports. A fee may apply to update existing customized report templates. 

Understanding QCI Interpret's manual and AI curation

The latest release of QCI Interpret for Hereditary includes AI enhanced coverage of thousands of rare disease genes. The below graphic illustrates the improved curation process for QCI Interpret, showing how all content is initially extracted using AI and machine learning, the most prevalent disease genes undergo human-certified curation, and all content undergoes rigorous quality control to ensure consistency and accuracy.

Learn more about QCI Interpret

QCI Interpret is clinical decision support software that combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered curation) to enable high-confidence variant interpretation and reporting. Advanced features enable clinical diagnostic labs to rapidly identify pathogenic variants, improve diagnostic yields, and reduce turnaround times. Panel- and sequencer-agnostic, QCI Interpret can be fully customized to accommodate gene panels, exomes, and genomes.

QCI Interpret for Hereditary


QCI Interpret for Oncology

2023 Clinical Hereditary Disease Diagnostics Summit

Part 1: October 12 | Part 2: November 9
A virtual event to help diagnostic labs learn how to safely apply AI to exome and genome sequencing workflows,

REGISTER NOW

Automating and scaling a comprehensive genomic profiling workflow can be a tedious and challenging process that requires lots of time and resources. However, an intelligent clinical decision support platform and on-demand expert support services can make all the difference.

In this webinar, learn about QIAGEN Clinical Insight (QCI) Interpret for Oncology, a clinical decision support platform that has been trusted to analyze and interpret more than 3 million patient molecular profiles worldwide. Unlike other commercial solutions, QCI Interpret for Oncology is powered by augmented molecular intelligence and offers in-software access to a team of variant scientists to assist you with rare or novel variant research, curation, and interpretation. The platform connects to the QIAGEN Knowledge Base—the highest quality genomic knowledge base in the industry—and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines. To help you further scale and reduce hands-on time, QCI Interpret for Oncology provides over 410,000 variant interpretation summaries that have all been reviewed by oncologists. This enables you to quickly build custom reports for your oncologists and their patients with the latest diagnostic and prognostic information, as well as biomarker-directed therapy and clinical trial recommendations.

By attending this webinar, you will:

Receive a step-by-step guide of how to go from VCF to final report using QCI Interpret for Oncology
Learn about the platform’s automated variant classification process
Learn how QIAGEN uses augmented molecular intelligence to enhance our expert curation process
See first-hand how to build a custom report with an opportunity to submit your own VCF file for a sample report